Hollis, the communications manager at George Mason University in Fairfax, Virginia, learned in July that he fell into a rare category of people whose blood could help scientists understand Covid-19 and potentially treat those who fall ill.
Covid-19, it seems, cannot harm him, said Dr. Lance Liotta, a George Mason University pathologist and bioengineer who is leading the school's clinical trials on antibodies.
Hollis, 54, a former journalist, learned that his blood is fortified with so-called super antibodies — antibodies that neutralize the virus, which, even when diluted 10,000 times, still resists Covid-19, Liotta said.
It is a medical phenomenon found in less than 5 percent of the population who have contracted the coronavirus, a study indicates
Potent antibodies found in people recovered from COVID-19
He unknowingly had Covid-19. Now his blood contains rare antibodies.
Covid-19, it seems, cannot harm him, said Dr. Lance Liotta, a George Mason University pathologist and bioengineer who is leading the school's clinical trials on antibodies.
Hollis, 54, a former journalist, learned that his blood is fortified with so-called super antibodies — antibodies that neutralize the virus, which, even when diluted 10,000 times, still resists Covid-19, Liotta said.
It is a medical phenomenon found in less than 5 percent of the population who have contracted the coronavirus, a study indicates
Potent antibodies found in people recovered from COVID-19
He unknowingly had Covid-19. Now his blood contains rare antibodies.